Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, Lindsay N. Carpp, Terri Wrin, Suqin Cai, Marcella Sarzotti‐Kelsoe, Charlene McDanal, Amanda Eaton, Rolando Pajón, John Hural, Christine M. Posavad, Katherine Gill, Shelly Karuna, Lawrence Corey, M. Juliana McElrath, Peter B. Gilbert, Christos J. Petropoulos, David C. Montefiori
Abstract
Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudovirus-based SARS-CoV-2 neutralization assays, with each trial using one of the two assays. Here we describe and compare the nAb titers obtained in the two assays. We observe that one assay consistently yielded higher nAb titers than the other when both assays were performed on the World Health Organization's anti-SARS-CoV-2 immunoglobulin International Standard, COVID-19 convalescent sera, and mRNA-1273 vaccinee sera. To overcome the challenge this difference in readout poses in comparing/combining data from the two assays, we evaluate three calibration approaches and show that readouts from the two assays can be calibrated to a common scale. These results may aid decision-making based on data from these assays for the evaluation and licensure of new or adapted COVID-19 vaccines.